• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Defibrotide Has a Role in COVID-19 Therapy.

作者信息

Macciò Antonio, La Nasa Giorgio, Oppi Sara, Madeddu Clelia

机构信息

Department of Gynecologic Oncology, Azienda di Rilievo Nazionale ed Alta Specializzazione (ARNAS) G. Brotzu, and the Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; Hematology and Transplant Center, Businco Hospital, ARNAS G. Brotzu, Cagliari, Italy.

出版信息

Chest. 2022 Aug;162(2):271-273. doi: 10.1016/j.chest.2022.04.143.

DOI:10.1016/j.chest.2022.04.143
PMID:35940644
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9353171/
Abstract
摘要

相似文献

1
Defibrotide Has a Role in COVID-19 Therapy.去纤苷在新冠病毒疾病治疗中发挥作用。
Chest. 2022 Aug;162(2):271-273. doi: 10.1016/j.chest.2022.04.143.
2
Defibrotide in the COVID-19 coagulopathy: What is the timing?去纤苷治疗新型冠状病毒肺炎凝血病：时机如何？
J Thromb Haemost. 2020 Nov;18(11):3113-3115. doi: 10.1111/jth.15100.
3
Fibrinolytic effects of defibrotide in atherosclerotic patients.去纤苷对动脉粥样硬化患者的纤溶作用。
Semin Thromb Hemost. 1991;17 Suppl 1:101-5.
4
Use of defibrotide in the treatment of acute myocardial infarction.
Semin Thromb Hemost. 1989 Oct;15(4):464-9. doi: 10.1055/s-2007-1002745.
5
[Use of defibrotide in the treatment of acute superficial thrombophlebitis of the legs].[去纤苷在治疗腿部急性浅表性血栓性静脉炎中的应用]
Minerva Chir. 1989 May 15;44(9):1379-84.
6
Defibrotide in extracorporeal circulation on healthy rabbits.去纤苷在健康兔体外循环中的应用。
Int J Artif Organs. 1989 Dec;12(12):749-54.
7
[Evaluation of the efficacy of profibrinolytic treatment with defibrotide in the therapy of thrombophlebitis].[去纤苷原纤维蛋白溶解治疗在血栓性静脉炎治疗中的疗效评估]
Clin Ter. 1988 Dec 15;127(5):355-61.
8
Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.一种新型抗血栓化合物去纤苷的临床药理学及作用机制
Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1-2):177-80.
9
Investigation of the fibrinolytic activity of defibrotide fractions.去纤苷片段的纤溶活性研究。
Gen Pharmacol. 1994 Dec;25(8):1617-20. doi: 10.1016/0306-3623(94)90363-8.
10
Update on the use of defibrotide.关于去纤维肽的应用进展。
Expert Opin Biol Ther. 2012 Mar;12(3):353-61. doi: 10.1517/14712598.2012.657623. Epub 2012 Jan 28.

引用本文的文献

1
Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.去纤苷用于预防和治疗血液系统恶性肿瘤及新冠肺炎中的内皮损伤
Biomolecules. 2025 Jul 14;15(7):1004. doi: 10.3390/biom15071004.
2
Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval.《COVID-19 治疗药物的作用机制综述：从发现到批准》。
J Korean Med Sci. 2024 Apr 15;39(14):e134. doi: 10.3346/jkms.2024.39.e134.

本文引用的文献

1
Defibrotide Therapy for SARS-CoV-2 ARDS.地塞米松联合肝素与单独使用肝素治疗 COVID-19 相关急性呼吸窘迫综合征的随机对照临床试验
Chest. 2022 Aug;162(2):346-355. doi: 10.1016/j.chest.2022.03.046. Epub 2022 Apr 9.
2
Potential role of macrophage activation in mediating thrombotic complications associated with the different vaccines against COVID-19.
Eur Rev Med Pharmacol Sci. 2021 Oct;25(20):6176-6178. doi: 10.26355/eurrev_202110_26987.
3
COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?COVID-19 和细胞因子风暴综合征：我们对卵巢癌中白细胞介素 6 的了解能否应用于此？
J Ovarian Res. 2021 Feb 8;14(1):28. doi: 10.1186/s13048-021-00772-6.
4
COVID-19: Staging of a New Disease.COVID-19：一种新型疾病的分期。
Cancer Cell. 2020 Nov 9;38(5):594-597. doi: 10.1016/j.ccell.2020.10.006. Epub 2020 Oct 10.
5
Defibrotide in the COVID-19 coagulopathy: What is the timing?去纤苷治疗新型冠状病毒肺炎凝血病：时机如何？
J Thromb Haemost. 2020 Nov;18(11):3113-3115. doi: 10.1111/jth.15100.
6
Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?新冠病毒相关凝血病的多因素发病机制：去纤苷在凝血障碍早期阶段能发挥作用吗？
J Thromb Haemost. 2020 Nov;18(11):3106-3108. doi: 10.1111/jth.15021.
7
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.COVID-19 导致的血管内皮损伤：补体、HIF-1 和 ABL2 是损伤的潜在途径和治疗靶点。
Ann Hematol. 2020 Aug;99(8):1701-1707. doi: 10.1007/s00277-020-04138-8. Epub 2020 Jun 24.
8
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.COVID-19 患者的病理性炎症：单核细胞和巨噬细胞的关键作用。
Nat Rev Immunol. 2020 Jun;20(6):355-362. doi: 10.1038/s41577-020-0331-4. Epub 2020 May 6.
9
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
10
Macrophage stimulating 1-induced inflammation response promotes aortic aneurysm formation through triggering endothelial cells death and activating the NF-κB signaling pathway.巨噬细胞刺激因子 1 诱导的炎症反应通过触发内皮细胞死亡和激活 NF-κB 信号通路促进主动脉瘤的形成。
J Recept Signal Transduct Res. 2020 Aug;40(4):374-382. doi: 10.1080/10799893.2020.1738484. Epub 2020 Mar 10.